Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10118086 | 1.00 | CA2 (0.36) | CA2CA1CA9 | |
| SCHEMBL10135572 | 1.00 | CA2 (0.36) | CA2CA1CA9 | |
| SCHEMBL6920159 | 1.00 | CA2 (0.36) | CA2CA1CA9 | |
| SCHEMBL7301263 | 1.00 | CA2 (0.36) | CA2CA1CA9 | |
| SCHEMBL18517496 | 0.86 | G6PD (0.35) | CA2CA1CA9 | |
| SCHEMBL18805837 | 0.86 | G6PD (0.35) | CA2CA1CA9 | |
| SCHEMBL8322168 | 0.83 | CA2 (0.34) | CA2CA1CA9 | |
| SCHEMBL17170416 | 0.83 | CA2 (0.34) | CA2CA1CA9 | |
| SCHEMBL21449039 | 0.83 | CA2 (0.34) | CA2CA1CA9 | |
| SCHEMBL2621335 | 0.83 | CA2 (0.34) | CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092819-A1 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | SANOFI SA (FR) | 2024-03-21 | — | — | US | disclosed |
| EP-4232455-A2 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | Sanofi (FR) | 2023-08-30 | — | — | EP | disclosed |
| US-20220259253-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | disclosed |
| WO-2022084331-A2 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | SANOFI (FR) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259253-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | CA2 2826/4885CA1 2856/4885CA9 1882/4885 |
| US-20240092819-A1 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | ASGR1, HAVCR2, SIGLEC7 | CA2 4829/4885CA1 4710/4885CA9 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.